Contents
The NextMed FTC settlement required a $150,000 payment and addressed allegations of misleading telehealth pricing, fabricated reviews and recurring-billing practices. NextMed sold access to telehealth services, with the case turning in part on what customers understood the price to include. The telling comparison is between what the offer promised, what the membership included and what happened when a customer tried to leave.
The Federal Trade Commission’s final decision and order, issued December 3, 2025, covers Southern Health Solutions, Inc., doing business as Next Medical and NextMed, and two company principals. This consumer-protection action concerned customers buying access to care on the strength of the platform’s pricing and marketing.
The order reached the founder, majority owner and chief executive who served until June 4, 2023, and the officer who succeeded him. For an insider describing decisions across that change in leadership, dates matter: who approved an offer, a billing practice or a cancellation policy belongs beside what the company did.
The order covers what NextMed tells customers its price includes: medical consultations, appointments, lab work or treatment. A membership, a consultation, a drug, laboratory work and follow-up are separate parts of the transaction. A price presented as covering treatment tells a different story from a price that buys access while leaving the customer to pay for the services and medication separately. That difference belongs in the offer the customer sees before paying.
In consumer healthcare, a subscription business can arrange treatment access while a professional practice supplies the clinical assessment and a management company handles scheduling, marketing or billing. For an inquiry into the NextMed access fee and prescription cost, we connect the advertised offer to the subscription terms, invoices and services included. What did the displayed price cover? Which parts of obtaining treatment carried another charge? Someone who worked on the offer or handled the resulting billing questions may be able to explain the gap between the promise and the purchase.
That is why the NextMed order reaches the sales machinery around care. The representation about what a price includes is something the platform controls.
The final order addresses support for claims about typical results and the alleged use of fabricated reviews. Those subjects concern what customers were told they could expect and whose experience appeared to support the offer.
The evidence has to reach behind the advertisement. We would compare the claimed result with the material used to support it, and a purported customer’s review with the account of how it was obtained.
An insider in marketing may know who approved the wording and what support accompanied it. Someone involved in review management may know how a review was obtained, selected or published.
For the customer deciding whether to pay, both representations serve the sale. The promised result says what to expect. The review gives that promise the apparent backing of someone who has already bought the service. A fabricated review, as alleged here, makes the sales pitch look like independent experience.
The NextMed cancellation order also covers how customers agreed to recurring charges and how they could cancel. The customer’s authorization, the terms governing continued charges and the way a cancellation request moves through the business are connected parts of the sale.
We follow a customer’s transaction from the offer and checkout version through the subscription terms to charge timestamps, cancellation requests and continuing access. Read together, those records can explain a dispute that a charge total alone leaves unresolved.
A customer-service employee may see the request to stop. A billing employee may see the later debit. A product or operations employee may understand why the system treated the account as active. We look for the connection among those views, including the policy or instruction that governed the response.
The same commercial issue appears in Cerebral’s consumer case. On May 8, 2025, the Federal Trade Commission reported refunds being sent to 40,249 consumers in connection with cancellation. The shared issue is the customer’s ability to end a paid subscription.
Continuing access matters when a customer is paying for continuing care. The comparison between what a subscription promises and what it delivers extends beyond the initial appointment to the follow-up included in the offer.
That issue became concrete in the New York attorney general’s November 26, 2024 agreement concerning SmileDirectClub customers. The agreement was with HPS Investment Partners as lenders’ agent, Healthcare Finance Direct and SDC U.S. SmilePay SPV. It addressed installment collection after promised monitoring and support had ceased. A payment schedule could continue after the service supporting it had stopped.
That is a different transaction from NextMed’s membership pricing, but it shows why continuing access belongs beside continuing charges in an investigation. The original sale and the later bill have to be read against what the customer was promised throughout the relationship.
An insider can connect a customer-facing promise to the decisions and systems behind it. For this kind of subscription case, we focus on the offer version, the price and included services, the basis for results claims, the review process, consent and what followed a request to cancel.
The strongest account may cross departments. Marketing may explain why particular words appeared beside the price. Operations may explain which services the membership delivered. Billing and customer service may explain the difference between a cancellation request and the account’s treatment afterward. We work with the person who understands those connections to identify what the documents show and which decisions they illuminate.
A subscription charge reaches the customer. A government health care claim reaches a public payer. For an insider whose information also concerns claims for consultations, prescriptions or tests, we examine the billed service and who paid for it alongside the offer made to the patient. That connection gives us a different question to investigate from the consumer-pricing issue in NextMed.
A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. That is a separate kind of case, and we work through which kind of claim your information supports with you.
If you worked with NextMed’s offers, reviews, billing or cancellation requests, talk with our whistleblower experts about what you saw. We build the case with you around the promises, charges and decisions you can explain, and bring in telehealth fraud whistleblower lawyers with the expertise your information calls for. We stay beside you as that inside knowledge becomes a case.